Structure-based design for binding peptides in anti-cancer therapy

15^th Annual European Pharma Congress

May 07-09, 2018 | Frankfurt, Germany

John Yu

Institute of Stem Cell and Translational Cancer Research, Taiwan

Posters & Accepted Abstracts: Pharmaceut Reg Affairs

Abstract :

The conventional anticancer therapeutics usually lack cancer specificity, leading to damage of normal tissues that patients find hard to tolerate. Ideally, anticancer therapeutics carrying payloads of drugs equipped with cancer targeting peptides can act like â�?�?guided missilesâ�? with the capacity of targeted delivery towards many types of cancers. Peptides are amenable for conjugation to nano drugs for functionalization, thereby improving drug delivery and cellular uptake in cancer-targeting therapies. Peptide drugs are often more difficult to design through molecular docking and in silico analysis than small molecules, because peptide structures are more flexible, possess intricate molecular conformations, and undergo complex interactions. In this report, the development and application of strategies for structure-based design of cancer-targeting peptides against GRP78 are discussed. This presentation will also cover topics related to peptide pharmacokinetics and targeting delivery, including molecular docking studies, features that provide advantages for in vivo use, and properties that influence the cancertargeting ability. Some advanced technologies and special peptides that can overcome the pharmacokinetic challenges have also been included. johnyu@cgmh.org.tw csctcr.john@cgmh.org.tw